Navigation Links
PharmAthene's Recombinant Butyrylcholinesterase (rBChE) Program the,Subject of Promising New Alzheimer's Research

/p>

Dr. Langermann continued, "These recent data suggest a promising new potential therapeutic application for rBChE, which we intend to explore further. Our next steps, in collaboration with Dr. Soreq and her group, will include evaluating rBChE in animal models of Alzheimer's disease. If the results continue to be encouraging, then it would allow us to expand applications of rBChE therapy to areas other than nerve agent toxicity resulting in broader commercial applications with important benefits to society."

The work conducted under the Alzheimer's research program is based on a patent owned by Yissum (the technology transfer company of The Hebrew University of Jerusalem), entitled "Human BChE Variants as Protectors from Amyloid Diseases," which has been licensed to PharmAthene.

About Protexia(R): Recombinant Human Butyrylcholinesterase (rBChE)

Protexia is a form of recombinant human butyrylcholinesterase (rBChE), a potent organophosphorus (OP) scavenger protein produced in the milk of transgenic goats, which is being developed for use as a prophylactic against acute organophosphorus (OP) nerve agent toxicity.

Preclinical research conducted by PharmAthene's development partners, the US Army Medical Research Institute of Chemical Defense (USAMRICD) and DRDC Suffield, Defence Research and Development Canada, have demonstrated the capability of Protexia to protect laboratory animals from the toxic effects of chemical nerve agents.

In these studies, pre-treatment with rBChE provided 100% survival against the nerve agents VX and soman. In post-exposure therapeutic studies, administration of rBChE following nerve agent exposure resulted in enhanced survival compared to control animals.

While the utility of BChE to protect against nerve agent exposure is well documented, a major limitation in its development has been the inability to produce it in commercial volumes due to limited raw material availability, low levels of the
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Pharmathenes Recombinant Butyrylcholinesterase (rBChE) Program the Subject of Promising New Alzheimers Research
2. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
3. Pieris Progresses Proprietary Asthma Program: Validation of Pulmonary Delivery of Anticalin-Based Protein Product Candidate
4. Major New Review Supports the Broader Potential of CeNeS COMT Inhibitor Discovery Programme
5. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
6. Amylin Pharmaceuticals to Present New Data from Broad Diabetes and Obesity Programs at ADA 2007
7. Ambrilia Highlights Encouraging Data for its HIV Integrase Inhibitor Program and Recent Developments at Annual Meeting
8. CuraGen Presents Update on Clinical Development Program for Belinostat
9. Hana Biosciences Presents Data On Two Programs At the American Society of Clinical Oncology Annual Meeting
10. Diatos Announces Positive Clinical Results for its DTS-201 Doxorubicin Prodrug Program
11. OXiGENE Abstracts Published in ASCO Program
Post Your Comments:
(Date:7/23/2008)... publication in July print edition of Clinical ...DIANAPOLIS, July 23 /- A Roche Diagno...N-terminal pro-B-type natriuretic peptide,(NT-proB...risk,stratification in predicting the risk of card...ted with non-steroidal anti-inflammatory drugs of,...
(Date:7/23/2008)...3 /- InCode BioPharmaceutics, Inc.,a...ced preclinical test,results demonstrating the uti...eatment of the rare chronic blood disorder paroxys...esults will be presented at the XXII,International...ber 28,2008., The only treatment currently avail...
(Date:7/22/2008).../- Nonin Medical, a leading innovator...an 20 years, has entered,the clinical testing phas...onal oxygen saturation. Today,s most common applic...ring of the regional blood oxygenation,in the brai...utcomes from an ongoing clinical study at the,Duke...
(Date:7/22/2008)... Lantus(R) and Apidra(R) Resulted in Significant, ..., Whatever the Algorithm ...ire/ -- Results from the "Adjust to,Target in Type...arbohydrate,Counting for Adjustment of Mealtime In...ican Diabetes Association,s (ADA) medical journal,...
Breaking Medicine Technology:Study Reveals Potential for NT-proBNP as a Marker to Predict Cardiovascular Risks From Anti-Inflammatory Drugs 2Study Reveals Potential for NT-proBNP as a Marker to Predict Cardiovascular Risks From Anti-Inflammatory Drugs 3Study Reveals Potential for NT-proBNP as a Marker to Predict Cardiovascular Risks From Anti-Inflammatory Drugs 4InCode BioPharmaceutics, Inc. Announces Key Data Supporting New Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) 2Nonin Medical Inc. Announces Entry Into the Cerebral Oximeter Market 2Newly Published Study Results Showed That Two Mealtime Insulin Dosing Algorithms Were Effective for Patients with Type 2 Diabetes 2Newly Published Study Results Showed That Two Mealtime Insulin Dosing Algorithms Were Effective for Patients with Type 2 Diabetes 3Newly Published Study Results Showed That Two Mealtime Insulin Dosing Algorithms Were Effective for Patients with Type 2 Diabetes 4Almost Family Announces Expansion of Revolving Credit Facility 7573 1Almost Family Announces Expansion of Revolving Credit Facility 7573 2Almost Family Announces Expansion of Revolving Credit Facility 7573 3Capital BlueCross HMO Plan is Ranked No 1 in Pennsylvania for Member Satisfaction 7571 1Capital BlueCross HMO Plan is Ranked No 1 in Pennsylvania for Member Satisfaction 7571 27 or 8 Hours of Sleep Best for Health 7569 1Sangamo BioSciences to Webcast Presentations at Investor and Analyst Briefing 2067 1Sangamo BioSciences to Webcast Presentations at Investor and Analyst Briefing 2067 2
...earch and Treatment of Rare but Devastating,Condit...ry University London,and the University of Leicest...ntial breakthrough in the treatment of a rare but,...dren and young,people. , In a world first, the cli...ave already treated one patient with promising,res...
...tner Forest Laboratories, Inc. Today,Announced the...cute,Ischemic Stroke) Study with the Compound Desm...N AG (Frankfurt Stock,Exchange, Prime Standard: PA...YSE: FRX) today announced topline results of,the D...y with the,compound Desmoteplase. The Phase III st...
Other Medicine Technology:World First Medical Treatment Announced by Researchers at Queen,Mary University London and University of Leicester 2World First Medical Treatment Announced by Researchers at Queen,Mary University London and University of Leicester 3World First Medical Treatment Announced by Researchers at Queen,Mary University London and University of Leicester 4World First Medical Treatment Announced by Researchers at Queen,Mary University London and University of Leicester 5Top Line Results of Phase III Study in Acute Ischemic Stroke,(DIAS-2) Do Not Demonstrate Difference Between Desmoteplase and,Placebo 2Top Line Results of Phase III Study in Acute Ischemic Stroke,(DIAS-2) Do Not Demonstrate Difference Between Desmoteplase and,Placebo 3Top Line Results of Phase III Study in Acute Ischemic Stroke,(DIAS-2) Do Not Demonstrate Difference Between Desmoteplase and,Placebo 4
(Date:7/25/2008)...ON, July 25 /PRNewswire/ -- The Elekta Family of C... treatment solutions at the 2008,American Associat...g,demonstrating how the joint forces of Elekta, I... therapy planning and delivery solutions that,stre...perience for,patients, as well as enhance clinicia...
(Date:7/25/2008)...ds fluid back-up in esophagus can cause immune sys...ay News) -- The first evidence linking gastroesoph...scovered by Duke University Medical Center researc...ns was first noted in the 1970s, and since then st...rcent of asthma patients also experience GERD symp...
(Date:7/25/2008)... The Retina Group of New York will...ted macular degeneration especially designed for s...e Public Library at 116 Merritts Road, Farmingdale.... Attendance is free and refreshments will be prov...6) 939-6100. , Hicksville...
(Date:7/25/2008)... This donation will be used to fac...ve services for children , ... ( www.ivci.com ), a leading integrator of enterp...tion video conferencing, telepresence, audio visua...announced today that it has donated video conferen...
Breaking Medicine News(10 mins):Health News:Elekta Family of Companies to Highlight Cancer Treatment Solutions at 2008 AAPM Annual Meeting 2Health News:Elekta Family of Companies to Highlight Cancer Treatment Solutions at 2008 AAPM Annual Meeting 3Health News:People With GERD More Likely to Develop Asthma 2Health News:Retina Group of New York To Present Seminar on Age-Related Macular Degeneration; The Leading Cause of Visual Loss in Seniors 2Health News:Retina Group of New York To Present Seminar on Age-Related Macular Degeneration; The Leading Cause of Visual Loss in Seniors 3Health News:Mt. Sinai's Children's Trauma Institute Treatment and Service Adaptation Center Receives Video Conferencing Donation From IVCi 2
... location for clinical trials for many pharmaceuti...s Squibb, GlaxoSmithkline, Eli Lilly are among tho...y. Currently over 226 clinical trials approved by...nd Drug Administration (FDA) are in India. Faced...
...hospital mortality is on the high during weekends.... not matching with the inflow// of the patients. T...is team from the University of Medicine and Dentis...ostis studied 231,164 patients who were admitted t...
...olysed casein proteins reduced the development of ...rom Germany. "The 3-year results of this large-sc...learly confirm the concept that the risk for [atop...thma can be reduced by nutritional intervention in...
...wn as "eSie Touch Elasticity Imaging" will be show...ropean Congress of Radiology) in Vienna//, Austria...n adjunct to regular breast ultrasound examination...ion of benign and malignant tissue. The method is ...
Other Medicine News:Health News:India Fast Become Prime Location for Clinical Trials, but Vigilance Called for 2Health News:Hydrolysed Casein Formula may Slash Eczema in Infants 2Health News:eSie Touch Elasticity Imaging, and a Promise of Avoiding Breast Biopsies 2
...ference laboratory and a worldwide leader in innov...fers an extensive test menu of highly complex and ...ology. Owned by the University of Utah, ARUP Labor...ion's university teaching hospitals and children's...
...ference laboratory and a worldwide leader in innov...fers an extensive test menu of highly complex and ...ology. Owned by the University of Utah, ARUP Labor...ion's university teaching hospitals and children's...
...ference laboratory and a worldwide leader in innov...fers an extensive test menu of highly complex and ...ology. Owned by the University of Utah, ARUP Labor...ion's university teaching hospitals and children's...
...ference laboratory and a worldwide leader in innov...fers an extensive test menu of highly complex and ...ology. Owned by the University of Utah, ARUP Labor...ion's university teaching hospitals and children's...
Medicine Products: